Cagrilintide is an investigational long-acting amylin analog developed by Novo Nordisk for weight management and type 2 diabetes. When paired with semaglutide (a GLP-1 receptor agonist) in a combination therapy known as CagriSema, it yields substantial weight loss. For research purposes only. Not for human consumption or veterinary use.